Weight Loss After 2 Months on Wegovy: What the Evidence Actually Says

The biggest myth: if the scales have barely shifted after two months, Wegovy isn't working for you

This is probably the question our prescribers hear most weeks, and it deserves a straight answer. Two months on Wegovy is, pharmacologically speaking, early days. The standard titration schedule starts at 0.25 mg weekly, steps to 0.5 mg at week five, then 1.0 mg at week nine, and continues climbing through 1.7 mg before reaching the 2.4 mg maintenance dose that produced the results in the large-scale trials. If you are at the eight-week mark, you may only just have reached 1.0 mg, a dose that is still primarily about tolerability, not maximum effect.

The STEP 1 trial, published in the New England Journal of Medicine, enrolled 1,961 adults and tracked weight change over 68 weeks. At the two-month point, average weight loss was modest. The steepest and most sustained reductions came between roughly weeks 8 and 36, once participants had been at or near the maintenance dose for long enough for appetite suppression to fully establish itself. Judging Wegovy's effectiveness at eight weeks is a little like judging a marathon runner at mile three.

That said, the myth cuts the other way too. Some people do see meaningful early losses (4% or 5% by week eight) and interpret that as a sign they should push doses faster. The titration schedule exists for a reason: moving too quickly increases the likelihood of gastrointestinal side effects significant enough to disrupt treatment entirely. Slow and steady is usually the route to the best long-term outcome, and your full Wegovy treatment overview explains that arc in detail.

What typical Wegovy weight loss in 2 months actually looks like, and why the range is wide

There is no single reliable figure for Wegovy weight loss at the two-month mark, because the published trials report outcomes at week 28, week 52 and week 68 rather than week 8. What we can say, drawing from the STEP 1 trial data and the titration schedule, is that most people reach roughly 3–6% of starting body weight lost by week eight. For someone starting at 100 kg, that is 3–6 kg. For someone starting at 130 kg, the absolute number will be higher even if the percentage is similar.

The spread is wide because several variables interact. How closely someone has followed the eating adjustments that accompany treatment matters. Sleep quality, stress levels and how much lean muscle mass a person has going in all affect the rate of fat loss. Some people experience enough nausea in the early weeks that their food intake drops sharply from the first injection; others feel almost no GI effects and find their appetite only gently reduced at lower doses. Neither response is wrong, they are just different.

If you want a longer-term perspective, the six-month Wegovy weight loss page sets out what the trial data shows once most patients are well-established on their maintenance dose. The gap between two months and six months is often where the most dramatic change happens, and our guide to Wegovy weight loss at three months covers what typically happens at the milestone that sits right in between.

Two months on Wegovy and no weight loss: when to flag it and what might be happening

Seeing little or no change after eight weeks is frustrating, and it is worth taking seriously rather than waiting it out indefinitely. Several practical things are worth checking before assuming the medicine is not working for you.

First, dose timing matters more than many people realise. Wegovy should be injected on the same day each week, and missed or inconsistently timed doses disrupt the steady-state blood levels the medicine depends on. Second, if nausea has been severe enough to cause repeated vomiting shortly after injection, absorption may have been compromised on some doses. Third, and this is straightforward: the calorie reduction that semaglutide supports is additive with the appetite suppression it creates, if the eating pattern has not shifted at all, the medicine has less to amplify.

Clinically, a small number of people have a reduced response to GLP-1 medicines at any dose. NICE's appraisal of semaglutide (TA875) notes that continuing treatment should be reviewed if less than 5% weight loss has occurred after six months at the maintenance dose. At two months you are not yet at that review point, but if you have lost nothing at all, that is still worth discussing with your prescriber now, not in four more months. You can also read about what happens when there is no loss at four months to understand the broader clinical picture.

Side effects at two months and what they mean for progress

The most common Wegovy side effects across the first eight weeks are gastrointestinal: nausea, loose stools, constipation, indigestion and burping. They typically peak shortly after starting or after each dose increase and ease within a week or two as your system adjusts. For most people, they are manageable rather than severe. The NHS semaglutide page lists these clearly and explains the circumstances in which you should seek medical help promptly.

One point worth knowing: nausea in the early weeks often reduces food intake beyond what you intended, which can mean faster initial loss for some, but also means the pace tends to moderate once the side effects settle. That is entirely normal. If your weight loss slowed between week four and week eight, it may simply reflect your body adjusting to the medicine rather than treatment failing.

Rare but serious effects require urgent attention. Severe, persistent abdominal pain that extends to your back (with or without vomiting) should not be waited out. Get medical help the same day. If you have questions about which symptoms to monitor as treatment progresses, the semaglutide information page covers the full side-effect profile in context. And if you are weighing up how your experience at two months compares to what happens in the period just after the eight-week mark, that resource covers what the next phase of treatment tends to bring.

For anyone still deciding whether to start or looking at the cost of continuing privately, Wegovy pricing in the UK lays out what private treatment typically involves. If you want to explore whether treatment is right for you, starting a free consultation with one of our GPhC-registered prescribers is the most direct route to a personal clinical view.